The Motley Fool··Jeff SiegelViking Therapeutics Emerges as Prime Takeover Target in Hot Obesity Drug Race
Viking Therapeutics emerges as prime takeover target for pharma giants seeking obesity drug exposure, with Phase 3 candidate and analyst price targets suggesting substantial acquisition premium potential.
LLYNVOVKTXbiotechPhase 3 trials